<DOC>
	<DOCNO>NCT00232076</DOCNO>
	<brief_summary>To assess efficacy safety oral OL27-400MEPC 3 mg/kg/day ( 2-5 mg/kg/day ) 2 divided dos daily 8 week patient severe adult atopic dermatitis . THIS STUDY IS NOT ENROLLING PATIENTS IN THE UNITED STATES</brief_summary>
	<brief_title>Verification Study Ciclosporin Atopic Dermatitis</brief_title>
	<detailed_description />
	<mesh_term>Dermatitis</mesh_term>
	<mesh_term>Dermatitis , Atopic</mesh_term>
	<mesh_term>Eczema</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>Appropriate definition/diagnosis criterion atopic dermatitis Japanese Dermatological Association Patients severe atopic dermatitis [ accord `` Guidelines Treatment Atopic Dermatitis 2002 , severity atopic dermatitis classify severe eruption associate severe inflammation ( lesion associate erythema , papule , erosion , infiltration , lichenification , etc . ) note least 30 % body surface day subject enrollment ] . Patients receive oral preparation , injection , inhaled preparation suppository steroids immunosuppressant tacrolimus hydrate ointment within 14 day subject enrollment Patients might receive oral/injection drug know enhance nephrotoxicity , increase serum potassium level , HMGCoA reductase inhibitor theophylline treatment period . Patients receive receive ultraviolet therapy ( PUVA therapy , etc . ) Patients hypertension , active infectional disease , gout etc . Other protocoldefined exclusion criterion may apply</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>64 Years</maximum_age>
	<verification_date>November 2011</verification_date>
	<keyword>Atopic Dermatitis , Ciclosporin ,</keyword>
</DOC>